New drug PHN-012 targets Hard-to-Treat cancers in first human trial
NCT ID NCT07127874
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 24 times
Summary
This early-stage study tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancers that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a cancer-killing agent directly to tumor cells. The main goals are to check safety and find the right dose, while also seeing if the drug can shrink tumors or slow disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
PHN-012-001 Site
RECRUITINGLos Angeles, California, 90033, United States
-
PHN-012-001 Site
NOT_YET_RECRUITINGSan Diego, California, 92037, United States
-
PHN-012-001 Site
RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
PHN-012-001 Site
RECRUITINGBoston, Massachusetts, 02114, United States
-
PHN-012-001 Site
RECRUITINGSt Louis, Missouri, 63108, United States
-
PHN-012-001 Site
RECRUITINGDurham, North Carolina, 27710, United States
-
PHN-012-001 Site
RECRUITINGPortland, Oregon, 97239, United States
-
PHN-012-001 Site
RECRUITINGNashville, Tennessee, 37203, United States
-
PHN-012-001 Site
RECRUITINGHouston, Texas, 77030, United States
-
PHN-012-001 Site
RECRUITINGSan Antonio, Texas, 78229, United States
-
PHN-012-001 Site
RECRUITINGFairfax, Virginia, 22031, United States
-
PHN-012-001 Site
RECRUITINGBarcelona, Community of Catalonia, 08023, Spain
-
PHN-012-001 Site
NOT_YET_RECRUITINGBarcelona, Community of Catalonia, 08023, Spain
-
PHN-012-001 Site
NOT_YET_RECRUITINGBarcelona, Community of Catalonia, 08035, Spain
-
PHN-012-001 Site
NOT_YET_RECRUITINGMadrid, Madrid, 28007, Spain
-
PHN-012-001 Site
RECRUITINGMadrid, Madrid, 28027, Spain
-
PHN-012-001 Site
NOT_YET_RECRUITINGMadrid, Madrid, 28034, Spain
-
PHN-012-001 Site
RECRUITINGMadrid, Madrid, 28040, Spain
-
PHN-012-001 Site
RECRUITINGMadrid, Madrid, 28050, Spain
-
PHN-012-001 Site
NOT_YET_RECRUITINGValencia, Valencia, 46009, Spain
-
PHN-012-001 Site
RECRUITINGValencia, Valencia, 46010, Spain
Conditions
Explore the condition pages connected to this study.